[Editor's note:Complete historical information on important medical device trial announcements is available from Informa’s Meddevicetracker. For an archive of previous Medtech Insight articles on medtech clinical trials, visit the Tracking Trials page.]
Axogen Expands RECON Study Of Avance Nerve Graft
The study will be expanded by 50 patients, for a total of 220 subjects, based on the recommendation of a statistician who reviewed an interim analysis. RECON is intended to support a Biologic License Application for Avance, a processed human nerve allograft for bridging severed peripheral nerves.
